MannKind Corporation to Participate in the Lytham Partners


DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Sept. 21, 2022 (GLOBE NEWSWIRE) — MannKind Corporation (Nasdaq: MNKD), an organization centered on the growth and commercialization of revolutionary therapeutic merchandise for sufferers with endocrine and orphan lung illnesses, introduced at present that its Chief Executive Officer, Michael Castagna, PharmD, will take part in the Lytham Partners Fall 2022 Investor Conference going down nearly on September 28-29, 2022.

The Company’s webcast presentation might be accessible for viewing at 9:00am ET on Wednesday, September 28, 2022, on the Company’s web site at Events & Presentations or The webcast can even be archived and accessible for replay.

Management might be collaborating in digital one-on-one conferences all through the occasion. To prepare a gathering with administration, please contact Lytham Partners at 1×

About MannKind Corporation

MannKind Corporation (Nasdaq: MNKD) focuses on the growth and commercialization of revolutionary therapeutic merchandise and gadgets to deal with severe unmet medical wants for these residing with endocrine and orphan lung illnesses.

We are dedicated to utilizing our formulation capabilities and machine engineering prowess to reduce the burden of illnesses resembling diabetes, pulmonary arterial hypertension (PAH) and nontuberculous mycobacterial (NTM) lung illness. Our signature applied sciences – dry-powder formulations and inhalation gadgets – provide speedy and handy supply of medicines to the deep lung the place they’ll exert an impact domestically or enter the systemic circulation.

With a passionate crew of Mannitarians collaborating nationwide, we’re on a mission to give individuals management of their well being and the freedom to reside life.

Please go to to be taught extra, and observe us on LinkedIn, Facebook, Twitter or Instagram.

See also  Monoclonal Antibody Market Present Scenario on Growth Analysis along with Key Industry Players

Company Contact:
Rose Alinaya, Investor Relations
(818) 661-5000


Source link


Please enter your comment!
Please enter your name here